Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies
Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of...
Saved in:
| Published in | Journal of translational medicine Vol. 8; no. 1; p. 4 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
15.01.2010
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of DC maturation by lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) induction in order to characterize the usefulness of mature DCs (mDCs) for immune therapy and to identify biomarkers for assessing the quality of mDCs.
Peripheral blood mononuclear cells were collected from 6 healthy subjects by apheresis, monocytes were isolated by elutriation, and immature DCs (iDCs) were produced by 3 days of culture with GM-CSF and IL-4. The iDCs were sampled after 4, 8 and 24 hours in culture with LPS and IFN-gamma and were then assessed by flow cytometry, ELISA, and global gene and microRNA (miRNA) expression analysis.
After 24 hours of LPS and IFN-gamma stimulation, DC surface expression of CD80, CD83, CD86, and HLA Class II antigens were up-regulated. Th1 attractant genes such as CXCL9, CXCL10, CXCL11 and CCL5 were up-regulated during maturation but not Treg attractants such as CCL22 and CXCL12. The expression of classical mDC biomarker genes CD83, CCR7, CCL5, CCL8, SOD2, MT2A, OASL, GBP1 and HES4 were up-regulated throughout maturation while MTIB, MTIE, MTIG, MTIH, GADD45A and LAMP3 were only up-regulated late in maturation. The expression of miR-155 was up-regulated 8-fold in mDCs.
DCs, matured with LPS and IFN-gamma, were characterized by increased levels of Th1 attractants as opposed to Treg attractants and may be particularly effective for adoptive immune cancer therapy. |
|---|---|
| AbstractList | BACKGROUND: Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of DC maturation by lipopolysaccharide (LPS) and interferon-γ (IFN-γ) induction in order to characterize the usefulness of mature DCs (mDCs) for immune therapy and to identify biomarkers for assessing the quality of mDCs. METHODS: Peripheral blood mononuclear cells were collected from 6 healthy subjects by apheresis, monocytes were isolated by elutriation, and immature DCs (iDCs) were produced by 3 days of culture with GM-CSF and IL-4. The iDCs were sampled after 4, 8 and 24 hours in culture with LPS and IFN-γ and were then assessed by flow cytometry, ELISA, and global gene and microRNA (miRNA) expression analysis. RESULTS: After 24 hours of LPS and IFN-γ stimulation, DC surface expression of CD80, CD83, CD86, and HLA Class II antigens were up-regulated. Th1 attractant genes such as CXCL9, CXCL10, CXCL11 and CCL5 were up-regulated during maturation but not Treg attractants such as CCL22 and CXCL12. The expression of classical mDC biomarker genes CD83, CCR7, CCL5, CCL8, SOD2, MT2A, OASL, GBP1 and HES4 were up-regulated throughout maturation while MTIB, MTIE, MTIG, MTIH, GADD45A and LAMP3 were only up-regulated late in maturation. The expression of miR-155 was up-regulated 8-fold in mDCs. CONCLUSION: DCs, matured with LPS and IFN-γ, were characterized by increased levels of Th1 attractants as opposed to Treg attractants and may be particularly effective for adoptive immune cancer therapy. Background Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of DC maturation by lipopolysaccharide (LPS) and interferon-[gamma] (IFN-[gamma]) induction in order to characterize the usefulness of mature DCs (mDCs) for immune therapy and to identify biomarkers for assessing the quality of mDCs. Methods Peripheral blood mononuclear cells were collected from 6 healthy subjects by apheresis, monocytes were isolated by elutriation, and immature DCs (iDCs) were produced by 3 days of culture with GM-CSF and IL-4. The iDCs were sampled after 4, 8 and 24 hours in culture with LPS and IFN-[gamma] and were then assessed by flow cytometry, ELISA, and global gene and microRNA (miRNA) expression analysis. Results After 24 hours of LPS and IFN-[gamma] stimulation, DC surface expression of CD80, CD83, CD86, and HLA Class II antigens were up-regulated. Th1 attractant genes such as CXCL9, CXCL10, CXCL11 and CCL5 were up-regulated during maturation but not Treg attractants such as CCL22 and CXCL12. The expression of classical mDC biomarker genes CD83, CCR7, CCL5, CCL8, SOD2, MT2A, OASL, GBP1 and HES4 were up-regulated throughout maturation while MTIB, MTIE, MTIG, MTIH, GADD45A and LAMP3 were only up-regulated late in maturation. The expression of miR-155 was up-regulated 8-fold in mDCs. Conclusion DCs, matured with LPS and IFN-[gamma], were characterized by increased levels of Th1 attractants as opposed to Treg attractants and may be particularly effective for adoptive immune cancer therapy. Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of DC maturation by lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) induction in order to characterize the usefulness of mature DCs (mDCs) for immune therapy and to identify biomarkers for assessing the quality of mDCs.BACKGROUNDDendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of DC maturation by lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) induction in order to characterize the usefulness of mature DCs (mDCs) for immune therapy and to identify biomarkers for assessing the quality of mDCs.Peripheral blood mononuclear cells were collected from 6 healthy subjects by apheresis, monocytes were isolated by elutriation, and immature DCs (iDCs) were produced by 3 days of culture with GM-CSF and IL-4. The iDCs were sampled after 4, 8 and 24 hours in culture with LPS and IFN-gamma and were then assessed by flow cytometry, ELISA, and global gene and microRNA (miRNA) expression analysis.METHODSPeripheral blood mononuclear cells were collected from 6 healthy subjects by apheresis, monocytes were isolated by elutriation, and immature DCs (iDCs) were produced by 3 days of culture with GM-CSF and IL-4. The iDCs were sampled after 4, 8 and 24 hours in culture with LPS and IFN-gamma and were then assessed by flow cytometry, ELISA, and global gene and microRNA (miRNA) expression analysis.After 24 hours of LPS and IFN-gamma stimulation, DC surface expression of CD80, CD83, CD86, and HLA Class II antigens were up-regulated. Th1 attractant genes such as CXCL9, CXCL10, CXCL11 and CCL5 were up-regulated during maturation but not Treg attractants such as CCL22 and CXCL12. The expression of classical mDC biomarker genes CD83, CCR7, CCL5, CCL8, SOD2, MT2A, OASL, GBP1 and HES4 were up-regulated throughout maturation while MTIB, MTIE, MTIG, MTIH, GADD45A and LAMP3 were only up-regulated late in maturation. The expression of miR-155 was up-regulated 8-fold in mDCs.RESULTSAfter 24 hours of LPS and IFN-gamma stimulation, DC surface expression of CD80, CD83, CD86, and HLA Class II antigens were up-regulated. Th1 attractant genes such as CXCL9, CXCL10, CXCL11 and CCL5 were up-regulated during maturation but not Treg attractants such as CCL22 and CXCL12. The expression of classical mDC biomarker genes CD83, CCR7, CCL5, CCL8, SOD2, MT2A, OASL, GBP1 and HES4 were up-regulated throughout maturation while MTIB, MTIE, MTIG, MTIH, GADD45A and LAMP3 were only up-regulated late in maturation. The expression of miR-155 was up-regulated 8-fold in mDCs.DCs, matured with LPS and IFN-gamma, were characterized by increased levels of Th1 attractants as opposed to Treg attractants and may be particularly effective for adoptive immune cancer therapy.CONCLUSIONDCs, matured with LPS and IFN-gamma, were characterized by increased levels of Th1 attractants as opposed to Treg attractants and may be particularly effective for adoptive immune cancer therapy. Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of DC maturation by lipopolysaccharide (LPS) and interferon-[gamma] (IFN-[gamma]) induction in order to characterize the usefulness of mature DCs (mDCs) for immune therapy and to identify biomarkers for assessing the quality of mDCs. Peripheral blood mononuclear cells were collected from 6 healthy subjects by apheresis, monocytes were isolated by elutriation, and immature DCs (iDCs) were produced by 3 days of culture with GM-CSF and IL-4. The iDCs were sampled after 4, 8 and 24 hours in culture with LPS and IFN-[gamma] and were then assessed by flow cytometry, ELISA, and global gene and microRNA (miRNA) expression analysis. After 24 hours of LPS and IFN-[gamma] stimulation, DC surface expression of CD80, CD83, CD86, and HLA Class II antigens were up-regulated. Th1 attractant genes such as CXCL9, CXCL10, CXCL11 and CCL5 were up-regulated during maturation but not Treg attractants such as CCL22 and CXCL12. The expression of classical mDC biomarker genes CD83, CCR7, CCL5, CCL8, SOD2, MT2A, OASL, GBP1 and HES4 were up-regulated throughout maturation while MTIB, MTIE, MTIG, MTIH, GADD45A and LAMP3 were only up-regulated late in maturation. The expression of miR-155 was up-regulated 8-fold in mDCs. DCs, matured with LPS and IFN-[gamma], were characterized by increased levels of Th1 attractants as opposed to Treg attractants and may be particularly effective for adoptive immune cancer therapy. Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of DC maturation by lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) induction in order to characterize the usefulness of mature DCs (mDCs) for immune therapy and to identify biomarkers for assessing the quality of mDCs. Peripheral blood mononuclear cells were collected from 6 healthy subjects by apheresis, monocytes were isolated by elutriation, and immature DCs (iDCs) were produced by 3 days of culture with GM-CSF and IL-4. The iDCs were sampled after 4, 8 and 24 hours in culture with LPS and IFN-gamma and were then assessed by flow cytometry, ELISA, and global gene and microRNA (miRNA) expression analysis. After 24 hours of LPS and IFN-gamma stimulation, DC surface expression of CD80, CD83, CD86, and HLA Class II antigens were up-regulated. Th1 attractant genes such as CXCL9, CXCL10, CXCL11 and CCL5 were up-regulated during maturation but not Treg attractants such as CCL22 and CXCL12. The expression of classical mDC biomarker genes CD83, CCR7, CCL5, CCL8, SOD2, MT2A, OASL, GBP1 and HES4 were up-regulated throughout maturation while MTIB, MTIE, MTIG, MTIH, GADD45A and LAMP3 were only up-regulated late in maturation. The expression of miR-155 was up-regulated 8-fold in mDCs. DCs, matured with LPS and IFN-gamma, were characterized by increased levels of Th1 attractants as opposed to Treg attractants and may be particularly effective for adoptive immune cancer therapy. Abstract Background Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of DC maturation by lipopolysaccharide (LPS) and interferon-γ (IFN-γ) induction in order to characterize the usefulness of mature DCs (mDCs) for immune therapy and to identify biomarkers for assessing the quality of mDCs. Methods Peripheral blood mononuclear cells were collected from 6 healthy subjects by apheresis, monocytes were isolated by elutriation, and immature DCs (iDCs) were produced by 3 days of culture with GM-CSF and IL-4. The iDCs were sampled after 4, 8 and 24 hours in culture with LPS and IFN-γ and were then assessed by flow cytometry, ELISA, and global gene and microRNA (miRNA) expression analysis. Results After 24 hours of LPS and IFN-γ stimulation, DC surface expression of CD80, CD83, CD86, and HLA Class II antigens were up-regulated. Th1 attractant genes such as CXCL9, CXCL10, CXCL11 and CCL5 were up-regulated during maturation but not Treg attractants such as CCL22 and CXCL12. The expression of classical mDC biomarker genes CD83, CCR7, CCL5, CCL8, SOD2, MT2A, OASL, GBP1 and HES4 were up-regulated throughout maturation while MTIB, MTIE, MTIG, MTIH, GADD45A and LAMP3 were only up-regulated late in maturation. The expression of miR-155 was up-regulated 8-fold in mDCs. Conclusion DCs, matured with LPS and IFN-γ, were characterized by increased levels of Th1 attractants as opposed to Treg attractants and may be particularly effective for adoptive immune cancer therapy. |
| ArticleNumber | 4 |
| Audience | Academic |
| Author | Han, Tae Hee Stroncek, David F Saunders, Stefanie Jin, Ping Ren, Jiaqiang Wang, Ena Marincola, Francesco M |
| AuthorAffiliation | 1 Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA 2 Department of Laboratory Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea |
| AuthorAffiliation_xml | – name: 1 Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA – name: 2 Department of Laboratory Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Ping surname: Jin fullname: Jin, Ping – sequence: 2 givenname: Tae Hee surname: Han fullname: Han, Tae Hee – sequence: 3 givenname: Jiaqiang surname: Ren fullname: Ren, Jiaqiang – sequence: 4 givenname: Stefanie surname: Saunders fullname: Saunders, Stefanie – sequence: 5 givenname: Ena surname: Wang fullname: Wang, Ena – sequence: 6 givenname: Francesco M surname: Marincola fullname: Marincola, Francesco M – sequence: 7 givenname: David F surname: Stroncek fullname: Stroncek, David F |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20078880$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kj1v1jAQgCNURD9gZEWRGJhS7NhxHAbUquKjUhELzNbZOaeukvitnSD13-M05VUDVBli-557dD7fcXYw-hGz7DUlp5RK8Z7yuikqWYtCFvxZdrTfHzxaH2bHMd4QUvKKNy-yw5KQWkpJjrLwzfdo5h5CHl03wjQHjLm3-bAs3djlLY5tcJMzucG-jx9yN-x6Z2Byfoy59SGfME4LOV1jfjtD76a7xbBNXKIBdg7jy-y5hT7iq4f_Sfbz86cfF1-Lq-9fLi_Orwpd1WIqODJKQFRacitBWg1WUE1kJbihoBGRG6wFQ24pNihbqRGA6bJqBKkbwU6yy9XberhRu-AGCHfKg1P3Bz50CkIqr0fFeGk4FU3TCMF1JTXRVJdGcwuSlYDJ9XF17WY9YGtwnAL0G-k2Mrpr1flfqpScVrJJgrNVoJ1_QrCNGD-o5f3U8n5KKp4U7x5qCP52Tj1Xg4tLa2FEP0dVMyZYU4sqkW9XsoN0OTdan5RmodV5WVJeCcbqRJ3-h0pfi4MzacqsS-ebhDePm7Av_s80JaBYARN8jAHtHqFELdP6z43YX7xx0_1gpUpc_0TWb_dL76I |
| CitedBy_id | crossref_primary_10_1146_annurev_immunol_110519_071134 crossref_primary_10_3390_cancers13071626 crossref_primary_10_1186_1471_2172_12_50 crossref_primary_10_1007_s10517_022_05451_0 crossref_primary_10_1007_s12195_020_00652_x crossref_primary_10_1111_brv_12176 crossref_primary_10_4161_21624011_2014_963424 crossref_primary_10_3389_fbioe_2020_00987 crossref_primary_10_1016_j_biopha_2023_115065 crossref_primary_10_4049_jimmunol_1200503 crossref_primary_10_4049_jimmunol_2001235 crossref_primary_10_1016_j_rvsc_2022_10_003 crossref_primary_10_4049_jimmunol_1101137 crossref_primary_10_1016_j_molimm_2022_01_003 crossref_primary_10_1038_s41698_017_0031_0 crossref_primary_10_1016_j_vetimm_2011_11_020 crossref_primary_10_1007_s00436_020_07016_4 crossref_primary_10_1016_j_cej_2021_130867 crossref_primary_10_3390_ijms22083978 crossref_primary_10_1016_j_mehy_2011_07_016 crossref_primary_10_1111_cpr_12358 crossref_primary_10_1007_s13577_019_00300_1 crossref_primary_10_1111_all_12643 crossref_primary_10_1016_j_ajpath_2012_09_007 crossref_primary_10_1038_s41467_022_35615_5 crossref_primary_10_1186_s41231_019_0049_0 crossref_primary_10_1016_j_celrep_2020_107613 crossref_primary_10_1172_jci_insight_138772 crossref_primary_10_4049_jimmunol_1500455 crossref_primary_10_1155_2013_972506 crossref_primary_10_1007_s10549_019_05129_8 crossref_primary_10_1002_smll_202006484 crossref_primary_10_1074_jbc_M110_213561 crossref_primary_10_1002_adtp_202300302 crossref_primary_10_1186_s12974_022_02421_1 crossref_primary_10_1007_s10753_015_0190_5 crossref_primary_10_1186_1755_8794_6_47 crossref_primary_10_1016_j_jdermsci_2019_11_012 crossref_primary_10_1111_j_1365_2249_2011_04382_x crossref_primary_10_3109_08830185_2011_561507 crossref_primary_10_1016_j_rvsc_2022_07_022 crossref_primary_10_1016_j_micpath_2020_104162 crossref_primary_10_1016_j_ymthe_2022_02_002 crossref_primary_10_1016_j_intimp_2018_02_015 crossref_primary_10_1002_iid3_735 crossref_primary_10_1016_j_bbrc_2022_06_037 crossref_primary_10_1007_s12032_012_0255_3 crossref_primary_10_1186_s12864_015_1673_3 crossref_primary_10_1021_acs_jmedchem_8b01448 crossref_primary_10_1158_2326_6066_CIR_20_0274 crossref_primary_10_1371_journal_pone_0086306 crossref_primary_10_3892_mmr_2018_8834 crossref_primary_10_7124_bc_00002C crossref_primary_10_1111_imm_12401 crossref_primary_10_1016_j_jcyt_2012_12_008 crossref_primary_10_1158_1078_0432_CCR_12_3181 crossref_primary_10_1186_s12879_020_05372_1 crossref_primary_10_1016_j_cellimm_2020_104149 crossref_primary_10_1158_2326_6066_CIR_18_0684 crossref_primary_10_1016_j_cellimm_2012_04_010 crossref_primary_10_1136_jitc_2021_004133 crossref_primary_10_1136_jitc_2024_009404 crossref_primary_10_1186_s13073_023_01259_3 crossref_primary_10_1016_j_drudis_2012_07_010 crossref_primary_10_1038_s41467_023_42881_4 crossref_primary_10_1002_advs_202002499 crossref_primary_10_1016_j_semcancer_2018_01_007 crossref_primary_10_1016_j_molmed_2010_07_007 crossref_primary_10_1371_journal_pcbi_1004050 crossref_primary_10_5045_kjh_2010_45_1_14 crossref_primary_10_1016_j_ymthe_2023_10_021 crossref_primary_10_4049_jimmunol_1303316 crossref_primary_10_1016_j_imbio_2021_152088 crossref_primary_10_1016_j_isci_2024_111289 crossref_primary_10_1111_bjh_17464 crossref_primary_10_1371_journal_pone_0022147 crossref_primary_10_1016_j_imbio_2015_09_023 crossref_primary_10_1159_000512451 crossref_primary_10_4161_onci_25771 crossref_primary_10_3390_cancers12061431 crossref_primary_10_3389_fimmu_2017_01152 crossref_primary_10_15789_1563_0625_PFO_2875 crossref_primary_10_3389_fimmu_2015_00528 crossref_primary_10_1007_s00262_010_0954_6 crossref_primary_10_1002_adbi_202200173 crossref_primary_10_1002_ijc_26101 crossref_primary_10_1016_j_autrev_2019_06_006 crossref_primary_10_4049_jimmunol_2100094 crossref_primary_10_1016_j_cellimm_2016_09_013 crossref_primary_10_1007_s40778_015_0024_2 crossref_primary_10_1016_j_immuni_2020_09_015 crossref_primary_10_1007_s10555_017_9716_7 crossref_primary_10_1016_j_athplu_2023_06_004 crossref_primary_10_1186_s13567_020_00864_z crossref_primary_10_1093_infdis_jiae441 crossref_primary_10_1002_adma_202411330 crossref_primary_10_1155_2024_5512422 crossref_primary_10_1155_2024_5537948 |
| Cites_doi | 10.1126/science.1139253 10.1084/jem.20072108 10.1186/1479-5876-2-17 10.1097/CJI.0b013e31819e1773 10.1073/pnas.95.25.14863 10.1186/gb-2003-4-5-p3 10.1172/JCI31205 10.4049/jimmunol.170.8.4069 10.1016/j.vaccine.2007.06.006 10.1038/nri1592 10.1158/0008-5472.CAN-07-6818 10.2353/ajpath.2007.070225 10.1038/ni722 10.1016/j.jim.2005.01.005 10.1016/j.coi.2007.10.010 10.1080/14653240310003053 10.1016/S0960-9822(02)00809-6 10.1182/blood.V96.6.2206 10.1016/j.bbmt.2006.10.023 10.1080/146532401753156377 10.4049/jimmunol.177.11.7665 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2010 BioMed Central Ltd. Copyright ©2010 Jin et al; licensee BioMed Central Ltd. 2010 Jin et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2010 BioMed Central Ltd. – notice: Copyright ©2010 Jin et al; licensee BioMed Central Ltd. 2010 Jin et al; licensee BioMed Central Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/1479-5876-8-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 4 |
| ExternalDocumentID | oai_doaj_org_article_342c416999664b58b0b1b2cb4fa832ae PMC2841589 oai_biomedcentral_com_1479_5876_8_4 A221456337 20078880 10_1186_1479_5876_8_4 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States South Korea |
| GeographicLocations_xml | – name: South Korea – name: United States |
| GroupedDBID | --- 0R~ 29L 2VQ 2WC 4.4 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 7X8 -A0 3V. ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 5PM PUEGO |
| ID | FETCH-LOGICAL-b576t-4e310a65b84f8a8fbaf61b08564c1abeee4ce763e4f1e9e8d8beaa3b259607963 |
| IEDL.DBID | RBZ |
| ISSN | 1479-5876 |
| IngestDate | Wed Aug 27 01:03:29 EDT 2025 Thu Aug 21 18:32:26 EDT 2025 Wed May 22 07:12:28 EDT 2024 Thu Jul 10 23:58:51 EDT 2025 Tue Jun 17 21:31:11 EDT 2025 Tue Jun 10 20:24:11 EDT 2025 Mon Jul 21 05:58:14 EDT 2025 Tue Jul 01 03:50:55 EDT 2025 Thu Apr 24 23:05:40 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b576t-4e310a65b84f8a8fbaf61b08564c1abeee4ce763e4f1e9e8d8beaa3b259607963 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://dx.doi.org/10.1186/1479-5876-8-4 |
| PMID | 20078880 |
| PQID | 733639765 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_342c416999664b58b0b1b2cb4fa832ae pubmedcentral_primary_oai_pubmedcentral_nih_gov_2841589 biomedcentral_primary_oai_biomedcentral_com_1479_5876_8_4 proquest_miscellaneous_733639765 gale_infotracmisc_A221456337 gale_infotracacademiconefile_A221456337 pubmed_primary_20078880 crossref_primary_10_1186_1479_5876_8_4 crossref_citationtrail_10_1186_1479_5876_8_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-01-15 |
| PublicationDateYYYYMMDD | 2010-01-15 |
| PublicationDate_xml | – month: 01 year: 2010 text: 2010-01-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2010 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | GJ Randolph (426_CR3) 2008; 20 J Banchereau (426_CR4) 2005; 5 K Holmstrom (426_CR21) 2009 EC Wong (426_CR9) 2001; 3 E Wang (426_CR14) 2002; 62 ML Albert (426_CR11) 2001; 2 JW Young (426_CR2) 2007; 13 RM O'Connell (426_CR24) 2008; 205 SI Hashimoto (426_CR1) 2000; 96 M Dauer (426_CR7) 2003; 170 R Muthuswamy (426_CR22) 2008; 68 G Dennis Jr (426_CR16) 2003; 4 TG Berger (426_CR10) 2005; 298 A Rodriguez (426_CR25) 2007; 316 TH Han (426_CR12) 2009; 32 K Kabashima (426_CR18) 2007; 171 E Gilboa (426_CR5) 2007; 117 M Ceppi (426_CR19) 2009 M Sugaya (426_CR17) 2006; 177 RT Martinez-Nunez (426_CR20) 2009 M Lagos-Quintana (426_CR23) 2002; 12 MB Eisen (426_CR15) 1998; 95 MC Panelli (426_CR13) 2004; 2 CA Nicolette (426_CR6) 2007; 25 T Felzmann (426_CR8) 2003; 5 12007417 - Curr Biol. 2002 Apr 30;12(9):735-9 17476349 - J Clin Invest. 2007 May;117(5):1195-203 15175100 - J Transl Med. 2004 Jun 2;2(1):17 18632653 - Cancer Res. 2008 Jul 15;68(14):5972-8 17114436 - J Immunol. 2006 Dec 1;177(11):7665-72 11590405 - Nat Immunol. 2001 Nov;2(11):1010-7 18299402 - J Exp Med. 2008 Mar 17;205(3):585-94 9843981 - Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 17222766 - Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):23-32 14578101 - Cytotherapy. 2003;5(5):391-8 18160272 - Curr Opin Immunol. 2008 Feb;20(1):52-60 17463290 - Science. 2007 Apr 27;316(5824):608-11 17669561 - Vaccine. 2007 Sep 27;25 Suppl 2:B47-60 10979967 - Blood. 2000 Sep 15;96(6):2206-14 19819280 - Hum Immunol. 2010 Jan;71(1):67-73 15847797 - J Immunol Methods. 2005 Mar;298(1-2):61-72 12028840 - Cytotherapy. 2001;3(1):19-29 12682236 - J Immunol. 2003 Apr 15;170(8):4069-76 19386588 - J Biol Chem. 2009 Jun 12;284(24):16334-42 12734009 - Genome Biol. 2003;4(5):P3 15803149 - Nat Rev Immunol. 2005 Apr;5(4):296-306 19193853 - Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2735-40 19342965 - J Immunother. 2009 May;32(4):399-407 17823289 - Am J Pathol. 2007 Oct;171(4):1249-57 12097256 - Cancer Res. 2002 Jul 1;62(13):3581-6 |
| References_xml | – volume: 316 start-page: 608 year: 2007 ident: 426_CR25 publication-title: Science doi: 10.1126/science.1139253 – volume-title: Proc Natl Acad Sci USA year: 2009 ident: 426_CR19 – volume: 205 start-page: 585 year: 2008 ident: 426_CR24 publication-title: J Exp Med doi: 10.1084/jem.20072108 – volume: 2 start-page: 17 year: 2004 ident: 426_CR13 publication-title: J Transl Med doi: 10.1186/1479-5876-2-17 – volume-title: Hum Immunol year: 2009 ident: 426_CR21 – volume: 32 start-page: 399 year: 2009 ident: 426_CR12 publication-title: J Immunother doi: 10.1097/CJI.0b013e31819e1773 – volume: 95 start-page: 14863 year: 1998 ident: 426_CR15 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.25.14863 – volume: 4 start-page: 3 year: 2003 ident: 426_CR16 publication-title: Genome Biol doi: 10.1186/gb-2003-4-5-p3 – volume: 117 start-page: 1195 year: 2007 ident: 426_CR5 publication-title: J Clin Invest doi: 10.1172/JCI31205 – volume: 170 start-page: 4069 year: 2003 ident: 426_CR7 publication-title: J Immunol doi: 10.4049/jimmunol.170.8.4069 – volume-title: J Biol Chem year: 2009 ident: 426_CR20 – volume: 25 start-page: B47 issue: Suppl 2 year: 2007 ident: 426_CR6 publication-title: Vaccine doi: 10.1016/j.vaccine.2007.06.006 – volume: 5 start-page: 296 year: 2005 ident: 426_CR4 publication-title: Nat Rev Immunol doi: 10.1038/nri1592 – volume: 68 start-page: 5972 year: 2008 ident: 426_CR22 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-6818 – volume: 171 start-page: 1249 year: 2007 ident: 426_CR18 publication-title: Am J Pathol doi: 10.2353/ajpath.2007.070225 – volume: 2 start-page: 1010 year: 2001 ident: 426_CR11 publication-title: Nat Immunol doi: 10.1038/ni722 – volume: 62 start-page: 3581 year: 2002 ident: 426_CR14 publication-title: Cancer Res – volume: 298 start-page: 61 year: 2005 ident: 426_CR10 publication-title: J Immunol Methods doi: 10.1016/j.jim.2005.01.005 – volume: 20 start-page: 52 year: 2008 ident: 426_CR3 publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2007.10.010 – volume: 5 start-page: 391 year: 2003 ident: 426_CR8 publication-title: Cytotherapy doi: 10.1080/14653240310003053 – volume: 12 start-page: 735 year: 2002 ident: 426_CR23 publication-title: Curr Biol doi: 10.1016/S0960-9822(02)00809-6 – volume: 96 start-page: 2206 year: 2000 ident: 426_CR1 publication-title: Blood doi: 10.1182/blood.V96.6.2206 – volume: 13 start-page: 23 year: 2007 ident: 426_CR2 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2006.10.023 – volume: 3 start-page: 19 year: 2001 ident: 426_CR9 publication-title: Cytotherapy doi: 10.1080/146532401753156377 – volume: 177 start-page: 7665 year: 2006 ident: 426_CR17 publication-title: J Immunol doi: 10.4049/jimmunol.177.11.7665 – reference: 15847797 - J Immunol Methods. 2005 Mar;298(1-2):61-72 – reference: 12734009 - Genome Biol. 2003;4(5):P3 – reference: 18299402 - J Exp Med. 2008 Mar 17;205(3):585-94 – reference: 12007417 - Curr Biol. 2002 Apr 30;12(9):735-9 – reference: 17463290 - Science. 2007 Apr 27;316(5824):608-11 – reference: 17476349 - J Clin Invest. 2007 May;117(5):1195-203 – reference: 19193853 - Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2735-40 – reference: 17669561 - Vaccine. 2007 Sep 27;25 Suppl 2:B47-60 – reference: 17823289 - Am J Pathol. 2007 Oct;171(4):1249-57 – reference: 17222766 - Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):23-32 – reference: 10979967 - Blood. 2000 Sep 15;96(6):2206-14 – reference: 14578101 - Cytotherapy. 2003;5(5):391-8 – reference: 19386588 - J Biol Chem. 2009 Jun 12;284(24):16334-42 – reference: 18160272 - Curr Opin Immunol. 2008 Feb;20(1):52-60 – reference: 17114436 - J Immunol. 2006 Dec 1;177(11):7665-72 – reference: 11590405 - Nat Immunol. 2001 Nov;2(11):1010-7 – reference: 9843981 - Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 – reference: 18632653 - Cancer Res. 2008 Jul 15;68(14):5972-8 – reference: 15175100 - J Transl Med. 2004 Jun 2;2(1):17 – reference: 15803149 - Nat Rev Immunol. 2005 Apr;5(4):296-306 – reference: 12028840 - Cytotherapy. 2001;3(1):19-29 – reference: 12682236 - J Immunol. 2003 Apr 15;170(8):4069-76 – reference: 19819280 - Hum Immunol. 2010 Jan;71(1):67-73 – reference: 19342965 - J Immunother. 2009 May;32(4):399-407 – reference: 12097256 - Cancer Res. 2002 Jul 1;62(13):3581-6 |
| SSID | ssj0024549 |
| Score | 2.27946 |
| Snippet | Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To... Background Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of... BACKGROUND: Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of... Abstract Background Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation... |
| SourceID | doaj pubmedcentral biomedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 4 |
| SubjectTerms | Adoptive Transfer Antigens, CD - genetics Antigens, CD - immunology Biomarkers - metabolism Cancer Care and treatment Cell Differentiation - drug effects Cell Differentiation - immunology Cells, Cultured Chemokines - genetics Chemokines - immunology Cytokines - genetics Cytokines - immunology Dendritic cells Dendritic Cells - drug effects Dendritic Cells - immunology Dendritic Cells - physiology Gene Expression Profiling Genetic aspects Granulocyte-Macrophage Colony-Stimulating Factor - immunology Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology Health aspects Histocompatibility Antigens Class II - genetics Histocompatibility Antigens Class II - immunology Humans Immune response Immunotherapy - methods Interferon-gamma - immunology Interferon-gamma - pharmacology Lipopolysaccharides - immunology Lipopolysaccharides - pharmacology Microarray Analysis MicroRNA MicroRNAs - genetics MicroRNAs - metabolism Monocytes - drug effects Monocytes - immunology Neoplasms - immunology Neoplasms - therapy Physiological aspects |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojxDC_IBwQWr8cZ2HG5tRVUhLScq9WZ5HFtUKlnU3R767zvjJKt1EeLCLYpndx3Pw99kx98w9gH6ukudUaJOTSuUqaOA4PEqIrwPYdH73GNp-d2cX6hvl_pyp9UX1YSN9MDjwh01ahEQNGRcrkBbqEHCIoBKHo3RR4q-uOfNydTMsqcz8JWq7YRGh5_ZNa052t4TVjw85n5d7E6ZxP_PUL2zV5V1lDsb09kz9nRClPx4fJJ99igOz9nj5fSf-Qt2s5w74HIq1shEnmu-SvwXXeLOxTH09LnjAafX-Osv_GqnzJwjquUb4uJASUSLfDyGeUffUH6Qj2e5MPV-yS7Ovv44PRdTpwUBmG9sUDOI8rzRYFWy3ibwyUhANGZUkB5ijCpEjERRJRm7aHsL0fsGMHcydYs-_IrtDashvmG89ooo7wzxjqkOQge97FP0WiZdo_Iq1hUr7n6PrBqOeK7LEXQ5R9pypC1nnarY51k7LkwU5tRJ49rlVMaah-Ift-Lzr_xF8IRUXUwl30BDdJMhun8ZYsU-kaE4Cgw4qeCn8w24LESx5Y4XRApvmqat2GEhiQ4dimE-m5qjIaqCG-Lqdu2IupLwo67Y69HytlOmV84WY3HF2sImi2cqR4arn5lOHAGK1LZ7-z8W4YA9GcsrpJD6kO1tbm7jO0RtG3ifHfQeHo9BIA priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLdgSIgL4nuBgXxAcMEQN7bjIE3TQEwTUjlRaTfLdmyYVNLRdhL773nPSbq6wIlbVL-0jt-Hfy99_j1CXrq2bGKjBCtjVTOhysCct3AVAN57P2lt6rE0_aJOZ-LzmTy7phQaFnD119QO-0nNlvO3v35eHYHDHyaH1-odF3XDJLg100zcJLdgU6qxmcFU6GvaPZmQ8EZ0pNvcvX3n3Ps8264Sq_-fsXtr88oLK7d2qpN75O4AMelxbxP3yY3QPSC3p8Of6A_Jcjq2xKVYvZGYPVd0EekPvIStjEIsalMLBIrv9Vfv6flW3TkFmEvXSM4BkgAfaX8u8wq_Ib-R9oe7IBd_RGYnn75-PGVD6wXmIAFZg6oA9lklnRZRWx2djYo7gGdKeG5dCEH4AKEpiMhDE3SrXbC2cpBMqbIGp35M9rpFF_YJLa1ADjyFRGSicb5xLW9jsJJHWbrSFaTJVtxc9DQbBomv8xHwQYPaMqgto40oyJtRO8YPnObYWmNuUm6j1a74q434-Cv_EPyAqs6mkj5YLL-ZwaVNJSYe4GzKGIWTGp6Fu4l3IloIkzYU5DUaikHbhUl5Oxx4gGVBzi1zPEGWeFVVdUEOMknwcJ8N09HUDA5hWVwXFpcrg1yWCChlQZ70lreZMr6D1hCcC1JnNpk9Uz7SnX9P_OKAWLjUzdP_UMwzcqcvs-CMywOyt15ehueA3tbuRfLL34tQRpg priority: 102 providerName: Scholars Portal |
| Title | Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20078880 https://www.proquest.com/docview/733639765 http://dx.doi.org/10.1186/1479-5876-8-4 https://pubmed.ncbi.nlm.nih.gov/PMC2841589 https://doaj.org/article/342c416999664b58b0b1b2cb4fa832ae |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swED7WFsZexn7PXRf0MLaXmVmxJMt7a0ZLGaSMsULYi5BkmRVaZzTpw_773sl2GmXsaS_GWOdE9ulO38mn7wDeuaao21qJvGjLKheqCLnzFs8Cwnvvp42NNZbm5-rsQnxdyMU9SdLOF3yu1ScuqjqXaLS5zsUeHEwFRnMUls9-3pPqyYhzN6Ijmebu7Tu72q-SyShy9v_tmbempjRtcmseOn0CjwcAyY57jT-FB6F7Bg_nwyfy53AzHwveMsrNiLydK7Zs2TWd4kTF0NM0scABo1X71Wd2uZVVzhDEsjVRb6AkgkPW77r8Q7-Q3sj6rVsYab-Ai9OTH1_O8qGwQu4wvFijIhDUWSWdFq22unW2Vdwh-FLCc-tCCMIHdDxBtDzUQTfaBWtLh6GSKio02Zew3y278BpYYQUx3CmiGRO187VreNMGK3krC1e4DOrkjZvfPYmGIVrrtAUtzJC2DGnLaCMy-Dhqx_iBsZwKZ1yZGLlotSv-fiM-_ss_BGek6qQr8QIOOzMYrCnF1CNYjfGgcFLjs3A39U60Fp2gDRl8oIFiyA9gp7wdtjPgayFGLXM8JQ54VZZVBkeJJNqvT5rZONQMNVHSWxeWtytDTJUEF2UGr_qRt-kyrTBrdL0ZVMmYTJ4pbekuf0X2cMQjXOr68D8U8wYe9UkUPOfyCPbXN7fhLWKztZvAXrWoJnAwOzn_9n0SVzjwOBd6Ei32DprlPVs |
| linkProvider | BioMedCentral |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NbxMxEB2VIkEviG8WCviA4MLSdWJ7vdxaRBWg6akVFRfL9nqhUrpBSXrg3zPj3Q1xECduq3g2sT32-I0z8wbglauLqqmUyItmXOZCFSF33uJTQHjv_ai2scbS9FRNzsXnC3mxA1-HXJh-BtEEkame9Rdiw__M7zZz0mfRkA_xY9321-qAi7LKJW7yXOfiBtwspSxjYtfRtz8kfDLi4rXoQL65_fpWFvwsObwix__flnzjKEvDLDfOreO7cKcHnOywG8A92Antfbg17Yf6ABbToUAuo1iOyPO5ZPOGXdEjHmwMLVMdCyIwuuVfvmeXG1HoDEEvWxFVB0oimGRdluYv-ob0RdaleqFn_hDOjz-efZjkfSGG3KE7skLFIQi0SjotGm1142yjuEOwpoTn1oUQhA9oqIJoeKiCrrUL1o4dulaqKHGLP4Lddt6GJ8AKK4gRTxEtmaicr1zN6yZYyRtZuMJlUCUzbn52pBuGaLDTFtS-IW0Z0pbRRmTwdtCO8T3DORXamJno6Wi1Lf56LT78yj8Ej0jVSVfiB_PFd9OvPzMWI4_gNvqPwkmNY-Fu5J1oLBpNGzJ4QwvFkN3ATnnbpz_gtBADlzkcEWe8Go_LDPYTSdzvPmlmw1Iz1ERBcm2YXy8NMVsSvJQZPO5W3rrLdCOt0VRnUCZrMhlT2tJe_ohs44hfuNTV0_9QzEu4PTmbnpiTT6dfnsFeF4DBcy73YXe1uA7PEdet3Iu4R38Da-xP6A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLfGkCYuiG8CA3xAcCEsbmzH4bYB1fjohBCTKi6W7dgwrUuntjvw3_Oek5S6iBM3q35pY78P_-z6_R4hz21T1KGWPC9CWeVcFj63zkDLA7x3btSYWGNpciKPT_nHqZjukOmQC9PPIIQgDNWz_kBs-J_59WZO-iwGcmi484PLJnT-r-QB41WdC_DyXOX8GrleCVFhbYOvR9__sPCJCIzXogP75vbjW2nws2T1iiT_f4fyjbUsvWe5sXCNb5GbPeKkh52J3CY7vr1D9ib9WO-SxWSokEvxMkck-lzSeaAX2ISVjUJoamJFBIrH_Ms39GzjGjoF1EtXyNUBkoAmaZem-Qu_IX2QdrlesDW_R07H77-9Pc77Sgy5hf3ICjQHKNBIYRUPyqhgTZDMAlqT3DFjvffceYhUngfma68aZb0xpYW9lSwq8PH7ZLedt_4hoYXhSIknkZeM19bVtmFN8EawIApb2IzUyYzry451QyMPdtoD6teoLY3a0krzjLwatKNdT3GOlTZmOm51lNwWf7EWH37lH4JHqOrkVeIH88UP3Xu4LvnIAbqNG0huhYKxMDtylgcDUdP4jLxEQ9EYONBoTZ__ANOCFFz6cISk8bIsq4zsJ5Lg8C7ppoOpaezCW3Ktn18tNVJbIr4UGXnQWd76lfFIWkGszkiV2GQyprSnPfsZ6cYBwDCh6kf_oZhnZO_Lu7H-_OHk02Nyo7uAwXIm9snuanHlnwCuW9mn0UV_A9C4T7M |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+signatures+of+maturing+dendritic+cells%3A+implications+for+testing+the+quality+of+dendritic+cell+therapies&rft.jtitle=Journal+of+translational+medicine&rft.au=Jin%2C+Ping&rft.au=Han%2C+Tae&rft.au=Ren%2C+Jiaqiang&rft.au=Saunders%2C+Stefanie&rft.date=2010-01-15&rft.pub=BioMed+Central+Ltd&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=8&rft.issue=1&rft.spage=4&rft.epage=4&rft_id=info:doi/10.1186%2F1479-5876-8-4&rft.externalDBID=n%2Fa&rft.externalDocID=oai_biomedcentral_com_1479_5876_8_4 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |